Global Orally Disintegrating Drug Market Growth (Status and Outlook) 2023-2029

Global Orally Disintegrating Drug Market Growth (Status and Outlook) 2023-2029

The global Orally Disintegrating Drug market size is projected to grow from US$ 1914.4 million in 2022 to US$ 3696.4 million in 2029; it is expected to grow at a CAGR of 9.9% from 2023 to 2029.

The orally disintegrating drug market is being driven by several factors. One of the primary drivers is the growing demand for convenient and patient-friendly medication delivery methods. Orally disintegrating drugs offer an advantage over traditional oral tablets as they quickly dissolve in the mouth without the need for water, making them easier to administer, particularly for individuals with swallowing difficulties, pediatric patients, and the elderly. Additionally, the increasing prevalence of chronic diseases and the need for efficient and immediate drug absorption have fueled the demand for orally disintegrating drugs. Furthermore, advancements in formulation technologies and taste-masking techniques have improved the palatability of these drugs, enhancing patient compliance. Overall, the demand for orally disintegrating drugs is driven by the need for convenience, improved patient experience, and enhanced drug delivery options in the pharmaceutical market.

An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken.

LPI (LP Information)' newest research report, the “Orally Disintegrating Drug Industry Forecast” looks at past sales and reviews total world Orally Disintegrating Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Orally Disintegrating Drug sales for 2023 through 2029. With Orally Disintegrating Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Orally Disintegrating Drug industry.

This Insight Report provides a comprehensive analysis of the global Orally Disintegrating Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Orally Disintegrating Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Orally Disintegrating Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Orally Disintegrating Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Orally Disintegrating Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Orally Disintegrating Drug market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Anti-Psychotics Drug
Anti-Epileptics Drug
Other

Segmentation by application
CNS Diseases
Gastrointestinal Diseases
CVS Diseases
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Johnson and Johnson
GSK
Otsuka
Vartris
Teva
Pfizer
Eli Lilly and Company
Merck
Eisai
AstraZeneca
Bristol-Myers Squibb
Conquer

Please note: The report will take approximately 2 business days to prepare and deliver.